Adam Goldstein is senior director, R&D, Thermo Fisher Scientific.

Adam Goldstein

3D Render of Therapeutic Antibody binding do PD-1 Molecule | Image Credit: ©Alpha Tauri 3D -stock.adobe.com. 

Downstream purification is increasingly defining the pace and performance of biologics manufacturing. However, as upstream processes deliver higher titers, downstream capacity and throughput have not kept pace, creating bottlenecks that delay clinical timelines, inflate manufacturing costs, and limit commercial potential. This mismatch is particularly acute as antibody-drug conjugates (ADC) and multispecific antibodies move toward commercialization, especially as each modality demands unique purification strategies, control parameters, and quality attributes.

Addressing these challenges requires a combination of process intensification, flexible system design, and smarter integration of analytics and automation. Developers who build scalability into their early process design, supported by real-time analytics, advanced process control, sustainable practices, and deep understanding of the design space, can successfully move from early-stage success to commercial manufacturing with significantly less rework and risk.

How Do Upstream Gains Create Downstream Constraints?

Over the past decade, upstream productivity improvements—largely driven by advances in cell line development, media, and perfusion—have fundamentally shifted the manufacturing balance. While upstream titers are continuing to rise dramatically,with typical fed-batch processes producing approximately 3–5 g/L and some optimized processes achieving up to 10–13 g/L

, downstream purification technologies have not scaled at the same rate, particularly in single-use environments.

For monoclonal antibodies (mAbs), the bottleneck is often capacity related. Larger product loads are processed through chromatography, filtration, and ultrafiltration/diafiltration (UF/DF) with finite throughput and footprint. In contrast, emerging modalities such as multispecific antibodies, ADCs and cell and gene therapies (CGTs) present purification challenges that are less about larger volumes and more about separation of these more complex molecules as compared to standard mAbs. Closely related impurities, structurally complex molecules, and sensitivity to processing conditions frequently force manufacturers to balance purity, yield, and process robustness.

How can Downstream Processing Be Intensified Without Increasing Complexity?

To keep pace, manufacturers are increasingly adopting downstream intensification strategies that reduce physical footprint while increasing effective throughput. Higher-capacity chromatography resins, flow-through polishing steps, and optimized clarification approaches enable more material to be processed with smaller columns and lower buffer volumes.

Providers should focus on enabling these strategies through scalable, single-use downstream systems that support higher productivity without adding operational burden. For example, chromatography platforms are designed to operate across a wide range of column sizes, allowing manufacturers to move from clinical to commercial scale using consistent hardware and control strategies. Similarly, advances in clarification technologies, such as integrating centrifugation and filtration, help deliver cleaner feed streams to downstream operations, reducing filter fouling and improving overall process efficiency.

Inline buffer dilution and the use of concentrated buffers further simplify operations by reducing buffer preparation and storage requirements, which are often overlooked contributors to downstream bottlenecks.

What Are the Benefits of Real-Time Analytics?

As downstream processes become more integrated, real-time insight is increasingly critical. Inline and at-line analytics allow manufacturers to monitor critical quality attributes in real time during processing rather than relying on offline sampling and delayed decision-making.

Raman-based process analytical technology (PAT) is being applied in downstream unit operations like UF/DF to monitor protein concentration and buffer composition in real time. By integrating these analytics directly with automation platforms, manufacturers can define precise process endpoints, reduce over-processing and minimize yield losses, particularly during final formulation steps where recovery from errors are difficult.

Over the past several years, PAT has become a critical enabler for accelerating development timelines and supporting scalable manufacturing. When paired with artificial intelligence (AI) and machine learning (ML), PAT data can be transformed from raw sensor readings into actionable process insights. This closed-loop approach shifts PAT from a passive monitoring tool to an active lever for de-risking scale-up and accelerating the path to commercial readiness.

While AI and ML are still emerging in downstream applications, manufacturers are already using advanced data analytics to accelerate process development and optimize operating parameters, driving smarter, faster decision-making at every stage of the purification train.

Scaling with Confidence from Clinical to Commercial

Designing downstream systems that scale smoothly remains a priority for biologics manufacturers. Consistency in materials, equipment, and control strategies across development stages simplifies technology transfer and reduces validation risk.

Platforms that can scale to support both small-scale development and large-scale commercial production, using the same core systems, allows teams to focus on process optimization rather than requalification at each scale. Implementing approaches that emphasize modular, scalable downstream solutions that can be deployed in flexible manufacturing environments helps support rapid transitions as pipelines evolve.

Single-use, skid-based purification systems with standardized interfaces enable manufacturers to quickly adapt their strategies as new modalities move through development, reducing capital investment and downtime between batches. By designing downstream platforms for flexibility from the outset, developers can accelerate commercial readiness while future-proofing their manufacturing strategy as the CGT landscape expands.

Regulatory expectations continue to support innovation when manufacturers demonstrate strong process understanding and control.

 For intensified or integrated downstream processes, this means validating unit operations individually while clearly defining their interactions within the overall process. Regulators expect detailed risk assessments and well-documented data flows that show how each purification step contributes to final product quality.

 They are also continuing to raise the bar on extractables, leachables, and overall sustainability, driving manufacturers and technology providers to innovate materials that meet stringent requirements while maintaining performance and reliability.

Collaboration, transparency, and rigorous validation enable manufacturers to gain speedy regulatory acceptance for new equipment and digital solutions, unlocking the full potential of next-generation downstream platforms.

Sustainability Through Process Efficiency

Sustainability considerations are becoming inseparable from downstream process design. Water and buffer consumption represents a significant portion of a facility’s environmental footprint, particularly for traditional bind-and-elute chromatography workflows.

Process intensification strategies, such as higher-capacity resins and flow-through chromatography, can dramatically reduce buffer usage. In some cases, switching from bind-and-elute to flow-through polishing steps can reduce water consumption by up to 70%,

 delivering both environmental and economic benefits. These gains illustrate how efficiency-driven downstream design aligns sustainability goals with operational performance.

Beyond buffers and water, energy consumption during purification—driven by extended cycle times, multiple chromatography runs, and inefficient unit operations—represents a hidden but substantial environmental cost. Continuous purification workflows, optimized chromatography cycles, and intelligent automation can reduce process duration and energy intensity compared to traditional batch approaches. At commercial scale, these efficiency gains translate into measurable reductions in carbon footprint alongside lower operating costs.

Progress in downstream purification depends on close collaboration between manufacturers, technology providers, regulators, and even competitors. While novel approaches may demonstrate technical promise in laboratory settings, broad adoption, and regulatory confidence typically follow once technologies are proven in real manufacturing environments. This reality underscores why industry partnerships and transparent data-sharing are essential to accelerating innovation across the sector.

The industry is increasingly coming together to define clear benchmarks for quality, share research on new materials and methods, as well as align on best practices for validation and process transfer. These collaborative efforts are driving the development of new standards and accelerating adoption of best-in-class solutions. By establishing common frameworks and shared learning, manufacturers reduce the risk and cost of technology implementation while building collective confidence in emerging approaches.

The most successful organizations recognize that transformation happens incrementally, not overnight. Rather than making sweeping changes that introduce unnecessary risk, they focus on scalable improvements that embed new technologies and practices alongside existing operations. This measured approach allows manufacturers to validate innovations in parallel, build internal expertise and scale solutions as confidence and capability grow.

During the next several years, downstream purification is likely to be shaped by incremental but impactful improvements rather than wholesale disruption.

Greater integration of unit operations, reduced pool volumes through single-pass tangential flow filtration (TFF), wider use of inline analytics, and continued movement toward semi-continuous processing will define near-term progress. These advances will be accelerated by industry collaboration across manufacturers, contract development and manufacturing organizations, technology providers, and regulators to establish common standards, share validation data, and reduce risk.

Perhaps most importantly, flexibility will be central to future downstream strategies. As therapeutic modalities diversify, manufacturers must be prepared to deploy different purification tools, such as columns, membranes, or alternative formats, within adaptable facilities. This requires intentional design choices during early process development, where scalability and modularity are embedded rather than retrofitted later.

Investments in flexible systems, integrated analytics and scalable platforms today will position manufacturers to meet the evolving demands of next-generation biologics, all while reducing rework, accelerating timelines, and managing costs. Developers who prioritize process understanding, build automation into their workflows, and design with commercial scale in mind will gain significant competitive advantage.

The path forward is not about finding the single best solution, but building resilient, adaptable operations capable of evolving alongside the rapid transformation of the biologics industry.

Sargent B. The current landscape of monoclonal antibody production

https://cellculturedish.com/the-current-landscape-of-monoclonal-antibody-production/

Bokelmann C, Ehsani A, Schaub J, and Stiefel F. Deciphering metabolic pathways in high-seeding-density fed-batch processes for monoclonal antibody production: A computational modeling perspective. 

Sponchioni M, Cavazzini A, and Catani M. 

Guidance for Industry: Process Validation: General Principles and Practices

https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf

Sharma N, et al. Systematic Approaches on Extractable and Leachable Study Designs in Pharmaceuticals and Medical Devices: A Review. 

Journal of Packaging Technology and Research

6. Rivera MN, Siemers A, Pleitt K, and Becerra A. Leveraging 3 distinct resins to provide effective impurity removal for mAbs and novel antibody derivatives. 

, Thermo Fisher Scientific, accessed February 20, 2026, 

https://www.bioprocessonline.com/doc/leveraging-distinct-resins-to-provide-effective-impurity-removal-for-mabs-and-novel-antibody-derivatives-0001

Articles

Downstream purification has become the principal rate-limiting step in biologics manufacturing as upstream titers surge, especially for ADCs and multispecifics that require tighter separations and gentler conditions. Closing the gap hinges on downstream intensification, modular single-use system design, and deployment of real-time analytics with automation to enable tighter control and faster scale-up. Regulatory acceptance increasingly depends on demonstrated process understanding, unit-operation interaction risk assessments, and robust extractables/leachables strategies. Efficiency-led redesign also advances sustainability by reducing buffer, water, and energy consumption.

Building resilient, adaptable operations capable of evolving alongside the rapid transformation of the biologics industry is key for downstream processing.